A point mutation in PTPRC (CD45) is associated with the development of multiple sclerosis
FASEB JOURNAL
Authors: Jacobsen, M; Schweer, D; Gaber, R; Schock, S; Ziegler, A; Oertel, WH; Sommer, N; Hemmer, B
Abstract
Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis
PHARMACOGENOMICS JOURNAL
Authors: Bek, S.; Bojesen, A. B.; Nielsen, J. V.; Sode, J.; Bank, S.; Vogel, U.; Andersen, V.
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects "1% of the Caucasian population. Over the last decades, the availability of biological drugs targeting the proinflammatory cytokine tumour necrosis factor a, anti-TNF drugs, has improved the treatment of patients with RA. However, one-third of the patients do not respond to the treatment. We wanted to evaluate the status of pharmacogenomics of anti-TNF treatment. We performed a PubMed literature search and all studies reporting original data on associations between genetic variants and anti-TNF treatment response in RA patients were included and results evaluated by meta-analysis. In total, 25 single nucleotide polymorphisms were found to be associated with anti-TNF treatment response in RA (19 from genome-wide association studies and 6 from the meta-analyses), and these map to genes involved in T cell function, NFKB and TNF signalling pathways (including CTCN5, TEC, PTPRC, FCGR2A, NFKBIB, FCGR2A, IRAK3). Explorative prediction analyses found that biomarkers for clinical treatment selection are not yet available.
COA
Publication 
Loading ......
